Adult T-cell Leukemia Following Satralizumab Treatment for Neuromyelitis Optica Spectrum Disorder

Area of Science:

• Immunology
• Oncology
• Neurology

Background:

• Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease.
• Satralizumab is an IL-6 inhibitor used to treat NMOSD.
• Adult T-cell leukemia (ATL) is a lymphoproliferative malignancy associated with Human T-lymphotropic virus type 1 (HTLV-1).

Purpose of the Study:

• To report a case of ATL developing after satralizumab treatment in an NMOSD patient.
• To investigate the potential link between IL-6 inhibition and HTLV-1 oncogenesis.
• To emphasize the importance of pre-treatment screening for HTLV-1 in NMOSD patients.

Main Methods:

• Case report of a 78-year-old woman with AQP4-antibody positive NMOSD.
• Analysis of clinical presentation, laboratory findings (lymphocytosis, HTLV-1 positivity, clonality), and treatment response.
• Review of potential mechanisms involving IL-6 inhibition and host defense.

Main Results:

• The patient developed acute-type ATL one month after starting satralizumab.
• HTLV-1 positivity and monoclonal proliferation were confirmed.
• The patient did not survive despite CHOP chemotherapy.

Conclusions:

• IL-6 inhibition with satralizumab may compromise host defense against HTLV-1 oncogenesis.
• ATL is a potential risk following satralizumab treatment, particularly in HTLV-1 endemic regions.
• HTLV-1 screening and clonality assessment are crucial before initiating satralizumab in NMOSD patients.